Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Conditions

Insulin Resistance 5Hyperglycemia 3Polycystic Ovary Syndrome 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Oligomenorrhea 1Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia 1Intracranial Aneurysm 1Hypoglycemia 1Hyperphagia 1Hyperinsulinism 1Hyperandrogenism 1Hirsutism 1Diabetes Mellitus, Type 2 1Diabetes Mellitus, Type 1 1Congenital Abnormalities 1Colorectal Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Pioglitazone 4Sulfonylurea Compounds 3Sitagliptin Phosphate 3Resistance Training 3Metformin 3Dipeptidyl-Peptidase IV Inhibitors 3Vildagliptin 2Sodium-Glucose Transporter 2 Inhibitors 2Nutritional Status 2Glucagon-Like Peptide-1 Receptor Agonists 2Blood Specimen Collection 2voglibose 1saxagliptin 1repaglinide 1miglitol 1metahexamide 1meglitinide 1mazdutide 1glymidine 1glisoxepide 1gliquidone 1glimepiride 1glibornuride 1desaminopancreozymin octapeptide 1alogliptin 1Urine Specimen Collection 1Troglitazone 1Tolbutamide 1Tolazamide 1Thiazolidinediones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Diabetes Mellitus, Type 2 × Insulin × Clear all
NCT07628556 2026-06-05

Antidiabetic Medications and Risk of Cancer

University of Pecs

Completed
74,799 enrolled

Diabetes Mellitus, Type 2, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡